Treatment-induced changes in 31P-MRS (magnetic resonance spectroscopy) spectra of sera from patients with acute leukemia

Abstract

31P-nuclear magnetic resonance (NMR) spectra were obtained in vitro from sera of 40 healthy volunteers and 30 patients with acute leukemia (AL) at the time of diagnosis and repeated up to 2-13 times during therapy. All spectra consisted of inorganic phosphate (Pi) peak (used as a reference peak) and two peaks from phospholipids (PL): one peak due to phosphatidylethanolamine and sphingomyelin (PE + SM) and second peak due to phosphatidylcholine (PC). Prior to initiation of therapy 31P spectra of sera of patients with acute leukemia differed from spectra of sera of normal individuals. Peak intensities of the PL were low in relation to Pi. During therapy leading to remission, resonance from PL progressively increased approximately to the spectral pattern in normal sera. Contrary to that, in non-responders the intensities of the phospholipids peaks remained unchanged. Long-term follow-up 31P-MRS studies showed not only a good correlation between this 31P-MRS evolution of sera and the response to the therapy but also showed changes in phospholipids' levels in the following days during and after therapy. Moreover, correlations were found between high-density lipoprotein (HDL), cholesterol (CHOL) and low-density lipoprotein (LDL) concentrations measured by conventional techniques and peak intensities of PC and of PE + SM acquired by 31P-MRS.

Low serum cholesterol levels predict inferior prognosis and improve NCCN‐IPI scoring in diffuse large B cell lymphoma

“…31 P‐magnetic resonance spectroscopy spectra was introduced by Kuliszkiewicz‐Janus et al . for analysis of phospholipid changes in neoplastic cells, and he discovered that concentrations of various phospholipids found in acute leukemia patients at the time of diagnosis were significantly lower than reference group and those benefited from CR …”

“…43 31 P-magnetic resonance spectroscopy spectra was introduced by Kuliszkiewicz-Janus et al for analysis of phospholipid changes in neoplastic cells, and he discovered that concentrations of various phospholipids found in acute leukemia patients at the time of diagnosis were significantly lower than reference group and those benefited from CR. 44,45 Targeting intracellular cholesterol might be an innovative approach for cancer treatment. Rink et al combined HDLlike nanoparticles with B-cell receptor (BCR) signaling inhibitor ibrutinib, which respectively targeted cellular cholesterol uptake and BCR-associated de novo cholesterol synthesis.…”

In Vitro and In Vivo 1H-MR Spectroscopic Examination of the Renal Cell Carcinoma

“…In another previous publication we already found systemic effect in patients with RCC by changes in phospholipid concentrations in blood (3). Other investigators found systemic changes in lipids of blood plasma in patients with thyroid cancer (18), hematological cancers (19)(20)(21) or digestive tract tumors (22).…”